Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function

Journal of Immunology

Volumn 195, Issue 1, 2015, Pages 174-184

  Stolberg, Valerie R ^a   McCubbrey, Alexandra L ^b   Freeman, Christine M ^a,c   Brown, Jeanette P ^c   Crudgington, Sean W ^c   Taitano, Sophina H ^b   Saxton, Bridget L ^d   Mancuso, Peter ^b,e   Curtis, Jeffrey L ^a,b,c  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d KALAMAZOO COLLEGE   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; FLUTICASONE; GLUCOCORTICOID; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANDROSTANE DERIVATIVE; CCL3 PROTEIN, MOUSE; CCL5 PROTEIN, MOUSE; CORTICOSTEROID; CXCL1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ACIDIFICATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; C57BL 6 MOUSE; CELL TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLONY FORMING UNIT; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; EFFEROCYTOSIS; IN VITRO STUDY; INFECTION RISK; INFLAMMATORY CELL; INHIBITION KINETICS; LUNG ALVEOLUS MACROPHAGE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHAGOLYSOSOME; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BACTERIAL COUNT; C57BL MOUSE; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LUNG; MICROBIOLOGY; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANDROSTADIENES; ANIMALS; APOPTOSIS; CHEMOKINE CCL3; CHEMOKINE CCL5; CHEMOKINE CXCL1; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FLUTICASONE; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-12; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS; PNEUMONIA, PNEUMOCOCCAL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; STREPTOCOCCUS PNEUMONIAE; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84932091853     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402217     Document Type: Article

References (105)

1. Calverley, P. M., J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, J. C. Yates, and J. Vestbo, TORCH investigators. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356: 775-789.
2. Wedzicha, J. A., P. M. Calverley, T. A. Seemungal, G. Hagan, Z. Ansari, and R. A. Stockley, INSPIRE Investigators. 2008. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 177: 19-26.
3. Crim, C., P. M. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, L. R. Willits, J. C. Yates, and J. Vestbo. 2009. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 34: 641-647.
4. Singanayagam, A., J. D. Chalmers, and A. T. Hill. 2010. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 103: 379-385.
5. Joo, M. J., D. H. Au, M. L. Fitzgibbon, and T. A. Lee. 2010. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir. Med. 104: 246-252.
6. Calverley, P. M., R. A. Stockley, T. A. Seemungal, G. Hagan, L. R. Willits, J. H. Riley, and J. A. Wedzicha, Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. 2011. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 139: 505-512.
7. Eurich, D. T., C. Lee, T. J. Marrie, and S. R. Majumdar. 2013. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested casecontrol study. Clin. Infect. Dis. 57: 1138-1144.
8. Yawn, B. P., Y. Li, H. Tian, J. Zhang, S. Arcona, and K. H. Kahler. 2013. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 8: 295-304.
9. Yang, I. A., M. S. Clarke, E. H. Sim, and K. M. Fong. 2012. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 7: CD002991.
10. Janson, C., K. Larsson, K. H. Lisspers, B. Ställberg, G. Stratelis, H. Goike, L. Jörgensen, and G. Johansson. 2013. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting b2 agonist: observational matched cohort study (PATHOS). BMJ 346: f3306.
11. Malo de Molina, R., E. M. Mortensen, M. I. Restrepo, L. A. Copeland, M. J. Pugh, and A. Anzueto. 2010. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur. Respir. J. 36: 751-757.
12. Chen, D., M. I. Restrepo, M. J. Fine, M. J. Pugh, A. Anzueto, M. L. Metersky, B. Nakashima, C. Good, and E. M. Mortensen. 2011. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am. J. Respir. Crit. Care Med. 184: 312-316.
13. Drummond, M. B., E. C. Dasenbrook, M. W. Pitz, D. J. Murphy, and E. Fan. 2008. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300: 2407-2416.
14. Singanayagam, A., J. D. Chalmers, A. R. Akram, and A. T. Hill. 2011. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur. Respir. J. 38: 36-41.
15. Loke, Y. K., C. S. Kwok, J. M. Wong, P. Sankaran, and P. K. Myint. 2013. Chronic obstructive pulmonary disease and mortality from pneumonia: metaanalysis. Int. J. Clin. Pract. 67: 477-487.
16. Mininõ, A. M., J. Xu, and K. D. Kochanek. 2010. Deaths: preliminary data for 2008. Natl. Vital Stat. Rep. 59: 1-52.
17. Torres, A., J. Dorca, R. Zalacaín, S. Bello, M. El-Ebiary, L. Molinos, M. Arévalo, J. Blanquer, R. Celis, M. Iriberri, et al. 1996. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am. J. Respir. Crit. Care Med. 154: 1456-1461.
18. Reissig, A., C. Mempel, U. Schumacher, R. Copetti, F. Gross, and S. Aliberti. 2013. Microbiological diagnosis and antibiotic therapy in patients with community-acquired pneumonia and acute COPD exacerbation in daily clinical practice: comparison to current guidelines. Lung 191: 239-246.
19. Torres, A., F. Blasi, W. E. Peetermans, G. Viegi, and T. Welte. 2014. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur. J. Clin. Microbiol. Infect. Dis. 33: 1065-1079.
20. Barbier, M., A. Agustí, and S. Albertí. 2008. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur. Respir. J. 32: 1283-1288.
21. To, M., Y. To, H. Yamada, C. Ogawa, M. Otomo, N. Suzuki, and Y. Sano. 2004. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern. Med. 43: 674-678.
22. O'Byrne, P. M., S. Pedersen, L. G. Carlsson, F. Radner, A. Thorén, S. Peterson, P. Ernst, and S. Suissa. 2011. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 183: 589-595.
23. McKeever, T., T. W. Harrison, R. Hubbard, and D. Shaw. 2013. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 144: 1788-1794.
24. Festic, E., V. Bansal, O. Gajic, and A. S. Lee, United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITGLIPS). 2014. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin. Proc. 89: 154-162.
25. Majo, J., H. Ghezzo, and M. G. Cosio. 2001. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur. Respir. J. 17: 946-953.
26. Yokohori, N., K. Aoshiba, and A. Nagai, Respiratory Failure Research Group in Japan. 2004. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 125: 626-632.
27. Calabrese, F., C. Giacometti, B. Beghe, F. Rea, M. Loy, R. Zuin, G. Marulli, S. Baraldo, M. Saetta, and M. Valente. 2005. Marked alveolar apoptosis/ proliferation imbalance in end-stage emphysema. Respir. Res. 6: 14.
28. Imai, K., B. A. Mercer, L. L. Schulman, J. R. Sonett, and J. M. D'Armiento. 2005. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur. Respir. J. 25: 250-258.
29. Hodge, S., G. Hodge, M. Holmes, and P. N. Reynolds. 2005. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur. Respir. J. 25: 447-454.
30. McCubbrey, A. L., and J. L. Curtis. 2013. Efferocytosis and lung disease. Chest 143: 1750-1757.
31. Newman, S. L., J. E. Henson, and P. M. Henson. 1982. Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages. J. Exp. Med. 156: 430-442.
32. Hu, B., J. Sonstein, P. J. Christensen, A. Punturieri, and J. L. Curtis. 2000. Deficient in vitro and in vivo phagocytosis of apoptotic T cells by resident murine alveolar macrophages. J. Immunol. 165: 2124-2133.
33. Hodge, S., G. Hodge, R. Scicchitano, P. N. Reynolds, and M. Holmes. 2003. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol. Cell Biol. 81: 289-296.
34. Hodge, S., G. Hodge, S. Brozyna, H. Jersmann, M. Holmes, and P. N. Reynolds. 2006. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur. Respir. J. 28: 486-495.
35. Hodge, S., G. Hodge, J. Ahern, H. Jersmann, M. Holmes, and P. N. Reynolds. 2007. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 37: 748-755.
36. Richens, T. R., D. J. Linderman, S. A. Horstmann, C. Lambert, Y. Q. Xiao, R. L. Keith, D. M. Boé, K. Morimoto, R. P. Bowler, B. J. Day, et al. 2009. Cigarette smoke impairs clearance of apoptotic cells through oxidantdependent activation of RhoA. Am. J. Respir. Crit. Care Med. 179: 1011-1021.
37. Petrusca, D. N., Y. Gu, J. J. Adamowicz, N. I. Rush, W. C. Hubbard, P. A. Smith, E. V. Berdyshev, K. G. Birukov, C. H. Lee, R. M. Tuder, et al. 2010. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J. Biol. Chem. 285: 40322-40332.
38. Janssen, W. J., K. A. McPhillips, M. G. Dickinson, D. J. Linderman, K. Morimoto, Y. Q. Xiao, K. M. Oldham, R. W. Vandivier, P. M. Henson, and S. J. Gardai. 2008. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am. J. Respir. Crit. Care Med. 178: 158-167.
39. Birge, R. B., and D. S. Ucker. 2008. Innate apoptotic immunity: the calming touch of death. Cell Death Differ. 15: 1096-1102.
40. Fadok, V. A., D. L. Bratton, A. Konowal, P. W. Freed, J. Y. Westcott, and P. M. Henson. 1998. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101: 890-898.
41. Cvetanovic, M., J. E. Mitchell, V. Patel, B. S. Avner, Y. Su, P. T. van der Saag, P. L.Witte, S. Fiore, J. S. Levine, and D. S. Ucker. 2006. Specific recognition of apoptotic cells reveals a ubiquitous and unconventional innate immunity. J. Biol. Chem. 281: 20055-20067.
42. Lucas, M., L. M. Stuart, A. Zhang, K. Hodivala-Dilke, M. Febbraio, R. Silverstein, J. Savill, and A. Lacy-Hulbert. 2006. Requirements for apoptotic cell contact in regulation of macrophage responses. J. Immunol. 177: 4047-4054.
43. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
44. Medeiros, A. I., C. H. Serezani, S. P. Lee, and M. Peters-Golden. 2009. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. J. Exp. Med. 206: 61-68.
45. McCubbrey, A. L., J. Sonstein, T. M. Ames, C. M. Freeman, and J. L. Curtis. 2012. Glucocorticoids relieve collectin-driven suppression of apoptotic cell uptake in murine alveolar macrophages through downregulation of SIRPa. J. Immunol. 189: 112-119.
46. Jonsson, S., D. M. Musher, A. Chapman, A. Goree, and E. C. Lawrence. 1985. Phagocytosis and killing of common bacterial pathogens of the lung by human alveolar macrophages. J. Infect. Dis. 152: 4-13.
47. Franke-Ullmann, G., C. Pförtner, P. Walter, C. Steinmüller, M. L. Lohmann-Matthes, and L. Kobzik. 1996. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. J. Immunol. 157: 3097-3104.
48. Koppe, U., N. Suttorp, and B. Opitz. 2012. Recognition of Streptococcus pneumoniae by the innate immune system. Cell. Microbiol. 14: 460-466.
49. Taylor, A. E., T. K. Finney-Hayward, J. K. Quint, C. M. Thomas, S. J. Tudhope, J. A. Wedzicha, P. J. Barnes, and L. E. Donnelly. 2010. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 35: 1039-1047.
50. Phipps, J. C., D. M. Aronoff, J. L. Curtis, D. Goel, E. O'Brien, and P. Mancuso. 2010. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect. Immun. 78: 1214-1220.
51. Hu, B., A. Punturieri, J. Todt, J. Sonstein, T. Polak, and J. L. Curtis. 2002. Recognition and phagocytosis of apoptotic T cells by resident murine tissue macrophages require multiple signal transduction events. J. Leukoc. Biol. 71: 881-889.
52. Freeman, C. M., J. L. Curtis, and S. W. Chensue. 2007. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am. J. Pathol. 171: 767-776.
53. Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M. Thompson, E. Kurt-Jones, J. C. Paton, M. R. Wessels, and D. T. Golenbock. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 100: 1966-1971.
54. Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1997. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65: 257-260.
55. van der Poll, T., C. V. Keogh, X. Guirao, W. A. Buurman, M. Kopf, and S. F. Lowry. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176: 439-444.
56. Sun, K., S. L. Salmon, S. A. Lotz, and D. W. Metzger. 2007. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun. 75: 1196-1202.
57. Palaniappan, R., S. Singh, U. P. Singh, R. Singh, E. W. Ades, D. E. Briles, S. K. Hollingshead, W. Royal, III, J. S. Sampson, J. K. Stiles, et al. 2006. CCL5 modulates pneumococcal immunity and carriage. J. Immunol. 176: 2346-2356.
58. Sung, S. S., S. M. Fu, C. E. Rose, Jr., F. Gaskin, S. T. Ju, and S. R. Beaty. 2006. A major lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J. Immunol. 176: 2161-2172.
59. Stolberg, V. R., B. Martin, P. Mancuso, M. A. Olszewski, C. M. Freeman, J. L. Curtis, and S. W. Chensue. 2014. Role of CC chemokine receptor 4 in natural killer cell activation during acute cigarette smoke exposure. Am. J. Pathol. 184: 454-463.
60. Marqués, J. M., A. Rial, N. Munõz, F. X. Pellay, L. Van Maele, H. Léger, T. Camou, J. C. Sirard, A. Benecke, and J. A. Chabalgoity. 2012. Protection against Streptococcus pneumoniae serotype 1 acute infection shows a signature of Th17- and IFN-g-mediated immunity. Immunobiology 217: 420-429.
61. Paats, M. S., I. M. Bergen, W. E. Hanselaar, E. C. van Zoelen, H. A. Verbrugh, H. C. Hoogsteden, B. van den Blink, R. W. Hendriks, and M. M. van der Eerden. 2013. T helper 17 cells are involved in the local and systemic inflammatory response in community-acquired pneumonia. Thorax 68: 468-474.
62. Henriques-Normark, B., and E. I. Tuomanen. 2013. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb. Perspect. Med. 3. pii: a010215.
63. Dransfield, M. T., S. Harnden, R. L. Burton, R. K. Albert, W. C. Bailey, R. Casaburi, J. Connett, J. A. Cooper, G. J. Criner, J. L. Curtis, et al; NIH COPD Clinical Research Network. 2012. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis. 55: e35-e44.
64. Mongardon, N., A. Max, A. Bouglé, F. Pène, V. Lemiale, J. Charpentier, A. Cariou, J. D. Chiche, J. P. Bedos, and J. P. Mira. 2012. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit. Care 16: R155.
65. Mizrachi-Nebenzahl, Y., S. Lifshitz, R. Teitelbaum, S. Novick, A. Levi, D. Benharroch, E. Ling, and R. Dagan. 2003. Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host. Clin. Exp. Immunol. 134: 23-31.
66. Chiavolini, D., G. Pozzi, and S. Ricci. 2008. Animal models of Streptococcus pneumoniae disease. Clin. Microbiol. Rev. 21: 666-685.
67. Finland, M. 1937. Significance of specific pneumococcus types in disease, including types IV to XXXII (Cooper). Ann. Intern. Med. 10: 1531-1543.
68. Austrian, R., and J. Gold. 1964. Pneumococcal bactermia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60: 759-776.
69. Weinberger, D. M., Z. B. Harboe, E. A. Sanders, M. Ndiritu, K. P. Klugman, S. Rückinger, R. Dagan, R. Adegbola, F. Cutts, H. L. Johnson, et al. 2010. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin. Infect. Dis. 51: 692-699.
70. Madhi, F., C. Godot, P. Bidet, M. Bahuaud, R. Epaud, and R. Cohen. 2014. Serotype 3 pneumococcal pleural empyema in an immunocompetent child after 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 33: 545-546.
71. Mancuso, P., G. B. Huffnagle, M. A. Olszewski, J. Phipps, and M. Peters-Golden. 2006. Leptin corrects host defense defects after acute starvation in murine pneumococcal pneumonia. Am. J. Respir. Crit. Care Med. 173: 212-218.
72. Hsu, A., D. M. Aronoff, J. Phipps, D. Goel, and P. Mancuso. 2007. Leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia. Clin. Exp. Immunol. 150: 332-339.
73. Amory-Rivier, C. F., J. Mohler, J. P. Bédos, E. Azoulay-Dupuis, D. Henin, M. Muffat-Joly, C. Carbon, and P. Moine. 2000. Nuclear factor-kappaB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection. Crit. Care Med. 28: 3249-3256.
74. Dockrell, D. H., M. Lee, D. H. Lynch, and R. C. Read. 2001. Immune-mediated phagocytosis and killing of Streptococcus pneumoniae are associated with direct and bystander macrophage apoptosis. J. Infect. Dis. 184: 713-722.
75. Dockrell, D. H., H. M. Marriott, L. R. Prince, V. C. Ridger, P. G. Ince, P. G. Hellewell, and M. K. Whyte. 2003. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J. Immunol. 171: 5380-5388.
76. Marriott, H. M., F. Ali, R. C. Read, T. J. Mitchell, M. K. Whyte, and D. H. Dockrell. 2004. Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J. 18: 1126-1128.
77. Matute-Bello, G., W. C. Liles, C. W. Frevert, S. Dhanireddy, K. Ballman, V. Wong, R. R. Green, H. Y. Song, D. R. Witcher, J. A. Jakubowski, and T. R. Martin. 2005. Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J. Infect. Dis. 191: 596-606.
78. Marriott, H. M., P. G. Hellewell, S. S. Cross, P. G. Ince, M. K. Whyte, and D. H. Dockrell. 2006. Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J. Immunol. 177: 6480-6488.
79. Winter, C., K. Taut, F. Länger, M. Mack, D. E. Briles, J. C. Paton, R. Maus, M. Srivastava, T. Welte, and U. A. Maus. 2007. FMS-like tyrosine kinase 3 ligand aggravates the lung inflammatory response to Streptococcus pneumoniae infection in mice: role of dendritic cells. J. Immunol. 179: 3099-3108.
80. Taut, K., C. Winter, D. E. Briles, J. C. Paton, J. W. Christman, R. Maus, R. Baumann, T. Welte, and U. A. Maus. 2008. Macrophage turnover kinetics in the lungs of mice infected with Streptococcus pneumoniae. Am. J. Respir. Cell Mol. Biol. 38: 105-113.
81. Herbold, W., R. Maus, I. Hahn, N. Ding, M. Srivastava, J. W. Christman, M. Mack, J. Reutershan, D. E. Briles, J. C. Paton, et al. 2010. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect. Immun. 78: 2620-2630.
82. Schabbauer, G., U. Matt, P. Günzl, J. Warszawska, T. Furtner, E. Hainzl, I. Elbau, I. Mesteri, B. Doninger, B. R. Binder, and S. Knapp. 2010. Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia. J. Immunol. 185: 468-476.
83. Bewley, M. A., H. M. Marriott, C. Tulone, S. E. Francis, T. J. Mitchell, R. C. Read, B. Chain, G. Kroemer, M. K. Whyte, and D. H. Dockrell. 2011. A cardinal role for cathepsin d in co-ordinating the host-mediated apoptosis of macrophages and killing of pneumococci. PLoS Pathog. 7: e1001262.
84. Brumshagen, C., R. Maus, A. Bischof, B. Ueberberg, J. Bohling, J. J. Osterholzer, A. D. Ogunniyi, J. C. Paton, T. Welte, and U. A. Maus. 2012. FMS-like tyrosine kinase 3 ligand treatment of mice aggravates acute lung injury in response to Streptococcus pneumoniae: role of pneumolysin. Infect. Immun. 80: 4281-4290.
85. Steinwede, K., S. Henken, J. Bohling, R. Maus, B. Ueberberg, C. Brumshagen, E. L. Brincks, T. S. Griffith, T. Welte, and U. A. Maus. 2012. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J. Exp. Med. 209: 1937-1952.
86. Tokairin, Y., Y. Shibata, M. Sata, S. Abe, N. Takabatake, A. Igarashi, T. Ishikawa, S. Inoue, and I. Kubota. 2008. Enhanced immediate inflammatory response to Streptococcus pneumoniae in the lungs of mice with pulmonary emphysema. Respirology 13: 324-332.
87. Sajjan, U., S. Ganesan, A. T. Comstock, J. Shim, Q. Wang, D. R. Nagarkar, Y. Zhao, A. M. Goldsmith, J. Sonstein, M. J. Linn, et al. 2009. Elastase- and LPS-exposed mice display altered responses to rhinovirus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L931-L944.
88. Aberdein, J. D., J. Cole, M. A. Bewley, H. M. Marriott, and D. H. Dockrell. 2013. Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin. Exp. Immunol. 174: 193-202.
89. Paterson, G. K., and C. J. Orihuela. 2010. Pneumococci: immunology of the innate host response. Respirology 15: 1057-1063.
90. Nibbering, P. H., M. T. van den Barselaar, J. S. van de Gevel, P. C. Leijh, and R. van Furth. 1989. Deficient intracellular killing of bacteria by murine alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 1: 417-422.
91. Hartshorn, K. L., E. Crouch, M. R. White, M. L. Colamussi, A. Kakkanatt, B. Tauber, V. Shepherd, and K. N. Sastry. 1998. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am. J. Physiol. 274: L958-L969.
92. Kuronuma, K., H. Sano, K. Kato, K. Kudo, N. Hyakushima, S. Yokota, H. Takahashi, N. Fujii, H. Suzuki, T. Kodama, et al. 2004. Pulmonary surfactant protein A augments the phagocytosis of Streptococcus pneumoniae by alveolar macrophages through a casein kinase 2-dependent increase of cell surface localization of scavenger receptor A. J. Biol. Chem. 279: 21421-21430.
93. Marriott, H. M., P. G. Hellewell, M. K. Whyte, and D. H. Dockrell. 2007. Contrasting roles for reactive oxygen species and nitric oxide in the innate response to pulmonary infection with Streptococcus pneumoniae. Vaccine 25: 2485-2490.
94. Peters-Golden, M., and P. Thebert. 1987. Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages. Am. Rev. Respir. Dis. 135: 1020-1026.
95. Kinchen, J. M., and K. S. Ravichandran. 2008. Phagosome maturation: going through the acid test. Nat. Rev. Mol. Cell Biol. 9: 781-795.
96. Standish, A. J., and J. N. Weiser. 2009. Human neutrophils kill Streptococcus pneumoniae via serine proteases. J. Immunol. 183: 2602-2609.
97. Canton, J. 2014. Phagosome maturation in polarized macrophages. J. Leukoc. Biol. 96: 729-738.
98. Marriott, H. M., and D. H. Dockrell. 2007. The role of the macrophage in lung disease mediated by bacteria. Exp. Lung Res. 33: 493-505.
99. Parker, D., F. J. Martin, G. Soong, B. S. Harfenist, J. L. Aguilar, A. J. Ratner, K. A. Fitzgerald, C. Schindler, and A. Prince. 2011. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. MBio 2: e00016-e11.
100. Koppe, U., K. Högner, J. M. Doehn, H. C. Müller, M. Witzenrath, B. Gutbier, S. Bauer, T. Pribyl, S. Hammerschmidt, J. Lohmeyer, et al. 2012. Streptococcus pneumoniae stimulates a STING- and IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J. Immunol. 188: 811-817.
101. Han, M. K., D. Postma, D. M. Mannino, N. D. Giardino, S. Buist, J. L. Curtis, and F. J. Martinez. 2007. Gender and chronic obstructive pulmonary disease: why it matters. Am. J. Respir. Crit. Care Med. 176: 1179-1184.
102. Han, M. K., E. A. Kazerooni, D. A. Lynch, L. X. Liu, S. Murray, J. L. Curtis, G. J. Criner, V. Kim, R. P. Bowler, N. A. Hanania, et al; COPDGene Investigators. 2011. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 261: 274-282.
103. Sin, D. D., D. Tashkin, X. Zhang, F. Radner, U. Sjöbring, A. Thorén, P. M. Calverley, and S. I. Rennard. 2009. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374: 712-719.
104. Cates, C. 2013. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 68: 499-500.
105. Nannini, L. J., T. J. Lasserson, and P. Poole. 2012. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 9: CD006829.